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Kidney Res Clin Pract 31 (2012) A16–A96A92not been rated yet. We aimed to evaluate the agreement between indirect
calorimetry (IC) and the predictive equations of Harris&Benedict (HB), Schoﬁeld
and WHO/FAO 1985. Fifty-seven elderly patients (38 males (67%); 6976 years)
on HD were included. The REE (kcal/day) estimated by the equations were
higher than that measured by IC: IC (1246 7288); HB (1443 7279); Schoﬁeld
(1357 7232); WHO 1985 (1384 7226) (Po0.05). The HB equation had the
lowest intraclass correlation coefﬁcient (ICC), the highest mean difference from
the REE measured by IC and a high frequency of overestimation (Table).Intraclass CC
(r; 95% CI)Bland-Altman* REE
overestimation
(%[n])HB x REE 0.53(0.31;0.69) 188(-331; 709 59.6 [34]
Schoﬁeld x REE 0.72(0.57;0.83) 112(-248; 472) 56.1 [32]
WHO 1985 x REE 0.74(0.60;0.84) 139(-222; 499) 59.6 [34]n
Mean difference and interquartile range; CI: conﬁdence intervalIn conclusion, all predicted equations overestimated the REE in elderly HD
patients. Among them, the HB equation had the worse agreement with IC.
http://dx.doi.org/10.1016/j.krcp.2012.04.620297
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The aim was to explore the relationships between malnutrition-
inﬂammation-athersclerosis (MIA) syndrome and low Triiodothyronine
(T3) syndrome in older peritoneal dialysis (PD) patients. A cross-sectional
survey was conducted in 109 PD patients visiting our clinic between March
to April, 2009. Subjective global nutritional assessment (SGA) and lean
body mass (LBM), arterial pulse pressure (PP), and serum thyroid proﬁles
were measured. All patients were divided into two groups by age (Z65 or
o 65years ). There were higher prevalence of malnutrition (assessed by
SGA, 28.6% vs 8.3%, Po0.05), greater PP (60.2715.0 vs 52.0720.2mmHg,
Po0.05), and higher levels of serum C-reactive protein (CRP, 9.02710.4 vs
3.4375.09 mg/L, Po0.05) in 49 older patients compared to the younger.
Higher prevalence of low T3 syndrome (42.9% vs 21.7%, Po0.05) and lower
levels of serum free T3 (fT3, 2.4170.35 vs 2.5770.31 pg/ml, Po0.05)
were found in older people. There were signiﬁcant correlations between
serum fT3 and LBM (r¼0.297, Po0.05), CRP (r¼0.302, Po0.05), and PP
(r¼0.284, Po0.05) in older people but not in the younger. In conclusion,
Older PD patients are more susceptible to MIA syndrome and low T3
syndrome than the younger, a vicious circle may exist between these two
syndromes in this population.
http://dx.doi.org/10.1016/j.krcp.2012.04.621298
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Hyperphosphataemia is associated with increased all-cause mortality in
patients with chronic kidney disease (CKD), but serum phosphate (P) levels
can be managed by dialysis, diet and the use of P binders. Serum P data
were obtained retrospectively from a US dialysis provider for the 9 months
following initiation of haemodialysis (HD) in CKD patients, who were then
grouped according to the variations in their serum P. Group baseline
characteristics and changes in P binder use over time were described.
Variations in average monthly serum P values from months 4 to 9 were
classiﬁed as either consistently in the target range (CT, 3.5–5.5 mg/dL),
consistently low (CL, o 3.5 mg/dL), consistently high (CH, 4 5.5 mg/dL),or varying between the low and target (LT), target and high (TH) or the low
and high ranges (LH). For each group, baseline characteristics and changes
in P binder use during the study were compared with CT (the reference
group) to identify differences.
In total, 47742 eligible patients were allocated to the six groups: CT,
7301; CL, 131; CH, 5001; LT, 6469; TH, 24469; LH, 4371. CH, TH, and LH
were signiﬁcantly younger than CT, with fewer comorbidities, higher
incidence of elevated parathyroid hormone (PTH) and higher mean serum
P; CH and TH also had higher levels of P binder use. CL and LT were older,
with more comorbidities, lower PTH levels and lower levels of P binder use
than CT. Overall, comparing months 8–9 with baseline (months 1–3), more
patients received P binder therapy (51.7 vs 35.0%), on a larger percentage of
days (50.0 vs 30.9%), but with little change in mean serum P (5.3 vs 5.2 mg/
dL). By group, mean serum P increased numerically in CH (7.5 vs 6.6 mg/
dL) and TH (5.6 vs 5.4 mg/dL) but decreased in other groups.
Serum P can be difﬁcult to control following initiation of HD. Patients
with elevated serum P were younger, and most had higher P binder use
than the reference group. Overall, binder use was lower than in other
studies of HD patients. Dietary education and higher doses of the most
effective P binders may be needed to improve P management.
http://dx.doi.org/10.1016/j.krcp.2012.04.622299
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Patients with chronic kidney disease undergoing haemodialysis have a
maximum recommended dietary phosphate (P) intake of 1000 mg/day and
a recommended protein intake of 1.2 g/kg/day. Achieving this level of
protein intake is associated with the best patient outcomes. However,
protein-containing foods also contain P, and elevated serum P is associated
with increased all-cause mortality. It is therefore important to manage the
levels of serum P while maintaining adequate levels of nutrition.
For different P binders, we estimated the dose and associated tablet
burden needed to remove excess P based on the maximum recommended
daily P intake. We also examined the implications for patient nutrition.
Published binding capacities of different P binders in healthy volunteers
ingesting up to 2000 mg/day P, are in the range of 26–135 mg P/g binder.
Assuming that 60% of ingested P is absorbed, and that haemodialysis three-
times weekly will remove 2400 mg P, a haemodialysis patient ingesting
1000 mg/day P will have a residual P burden of 257 mg/day. To bind this,
patients would require a maximum of 3 x 1000 mg lanthanum carbonate
tablets, or approximately 9 x 400 mg calcium carbonate tablets, or
approximately 9 x 800 mg sevelamer hydrochloride tablets.
The recommended protein intake for a 70 kg haemodialysis patient is
84 g/day. A realistic estimate of the average P content of a typical diet is
15 mg/g protein, which equates to a P intake of 1260 mg/day. This is
considerably in excess of the recommended limit and, depending on
vitamin D status more than 60% may be absorbed, further adding to the
residual P burden.
The availability of binding capacity data for P binders, presents
physicians with the possibility of tailoring doses of binder to a patient’s
diet, facilitating sufﬁcient intake of dietary protein while maintaining a
neutral P balance. Use of high-capacity binders, such as lanthanum
carbonate, would minimize the tablet burden faced by patients and this
may also encourage adherence.
http://dx.doi.org/10.1016/j.krcp.2012.04.623300
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